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Previewsacids may also be concealed from the
host sensors at certain phases of the viral
life cycle by the incoming viral capsid
structure or by association with the prein-
tegration complex. Cyclophilin A, a mole-
cule long known to be involved in retro-
viral replication, has recently been
suggested to be involved in sensing retro-
viral infections (Manel et al., 2010), as has
TRIM5, a molecule that also has direct
antiretroviral activity (Pertel et al., 2011).
The findings of Kane et al. are an impor-
tant addition to our growing under-
standing of how cells detect the presence
of these lethal pathogens.10 Immunity 35, July 22, 2011 ª2011 ElsevieREFERENCES
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Deliberate redirection of T cell responses to human immunodeficiency virus-1 might enhance immunity and
thus aid viral containment. Dahirel et al. (2011) identify candidate antigens to achieve this with a theory
derived from physics.The elephant in the conference room for
those working with human immunodefi-
ciency virus (HIV) vaccines is that despite
30 years of intense scientific effort and
extremely generous global funding, we
have no tenable vaccine. This research
effort and the money spent have told us
much about the virus and the immunity it
evokes, but there has been no translation
to a preventative vaccine. So far three
large trials have failed to demonstrate
protection against HIV-1 infection.
We still do not knowwhat form of immu-
nity a vaccine must engender to prevent
infection. The STEP trial has severely
tempered enthusiasm for T cell vaccines
(Buchbinder et al., 2008), but despite the
negative result, the boosting or enhance-
ment of anti-HIV cytotoxic T cells (CTLs)
remains a stoical ambition ofmany groups.
The enduring inspiration for this aim is the
fact that HIV-1-specific CTLs do seem
responsible for containment of the infec-tion. Uncommonly, some individuals sup-
press HIV replication so well that virus is
not detectable in their plasma. This
phenomenon has been attributed, in part,
to HIV-1-specific CTLs. Many of these
patients have particular human leucocyte
antigen (HLA) class I molecules that confer
benefit in ways we barely understand. If
CTL responsescouldbeartificially boosted
or redirected to the ‘‘right’’ antigens, then
could protective immunity be induced or
chronically infected patients be converted
into ‘‘elite controllers’’?
Natural and artificially induced CTLs
select retroviral mutants that evade im-
mune recognition (Phillips et al., 1991); the
impact on clinical progression that immune
escape confers is not clear. In an apparent
paradox, immune escape might even slow
progression, depending on the precise
mutations that confer this effect (Frater
et al., 2007). Methods that quantify viral
replicative capacity, or ‘‘fitness,’’ ex vivohave shown that immune escape muta-
tions in certainHIVepitopesare associated
with fitness costs whereas others exact no
price. Three findings in patients strongly
support the notion that some immune
escape mutants impair virus replication:
(1) the reversion of mutations upon trans-
mission to new hosts who do not carry
the same HLA class I alleles (Leslie et al.,
2004), (2) preliminary observations that
immune escape may revert in end-stage
AIDS as the immune system weakens
(Huang et al., 2011), and (3) the identifica-
tion of compensatory viral mutations that
partially or fully reinstate viral fitness (Craw-
ford et al., 2007). There is a dynamic
between the triad of CTL pressure, viral
adaptation, and viral fitness. The outcome
of this battle will influence, perhaps mark-
edly, clinical progression (Figure 1).
In the 108th edition of the Proceedings
of the National Academy of Science, Da-









Figure 1. A Triad of Forces, the Balance of
which May Determine HIV-Related Disease
Progression
The simple figure models the interaction between
the selection pressure imposed by the immune
system (in this case CTLs), viral adaptation to
escape, and the cost to viral replicative capacity
incurred. According to the relative strengths of
the interconnecting arrows, clinical progression
may progress at different speeds from rapid
progression to elite control.
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Previewsrandom matrix theory (RMT) to a study of
HIV viral evolution. RMT is a mathematical
technique that filters out the noise present
in largegroupsof varyingdata to findother-
wise hidden correlations. The authors use
RMT to search the HIV-1 genome for sites
of variation that evolve together, in the
same way financial stocks within either
the building or pharmaceutical sectors
might covary independently from other
sectors. By grouping mutations in HIV-1
into these ‘‘sectors,’’ they identify con-
served regions of the genome that would
be candidates for vaccine antigens. This
analysis is predicated on the idea that HIV
adaptation to CTL pressure is ultimately
limited by fitness costs. The resulting vac-
cine-induced immunity would select for
mutants that carry high fitness costs and
where compensatory mutations are not
tolerated because of structural constraints.
In the first instance the authors analyze
1,600 HIV subtype B Gag sequences (500
amino acids long) from the Los Alamos
laboratories database and identify events
where mutations occur together more
frequently than would be expected from
their independent distributions. A correla-
tion matrix of all possible combinations of
polymorphic amino acid sites is then pro-
duced. Where mutations become linked a
cluster is defined, called an ‘‘eigenvector,’’which itself has an ‘‘eigenvalue’’ to reflect
the strength of correlations linking the indi-
vidual sites. The authors, however, had to
account for noise and phylogenetic rela-
tionships between sites (which give the
strongest eigenvectors), because this can
lead to misleading associations. This is
where RMT came in useful, to define the
boundarybetweeneigenvectors that repre-
sented noise from those representing true
signal. Although they identified 289 sites in
HIV Gag that did not coevolve, they found
collections of mutating sites (sectors) that
did. A key point is that HLA-associated
footprint sites—i.e., those that reflect viral
adaptation to CTL-imposed immune pres-
sure—were only weakly associated with
sectors and were effectively excluded.
The use of RMT to ‘‘clean’’ the resulting
matrix of coevolving sites of noise resulted
in some interesting trends. The authors
identify five sectors within the HIV-1 Gag
proteome that have evolved indepen-
dently of each other. These five sectors
contain conserved amino acid loci (mean
conservation within the sectors of at least
95%), although they vary in the degree to
which sites covary. In particular, sites
with a ‘‘negative correlation’’ (i.e., muta-
tions that are found together less fre-
quently than might be expected from their
individual frequencies) are felt tobe impor-
tant because they reflect evolutionary
constraint. Of the five sectors, the authors
identify Gag sector 3—a collection of 57
amino acid sites—to have the strongest
negative correlations, suggesting that
this is the region of the HIV proteome
under greatest conservation and therefore
a good target for a vaccine.
The identification of sector 3 is sup-
ported by structural modeling showing
that 68% of the associated amino acid
sites are at key interfaces of the p24
protein hexamers, potentially explaining
the observed evolutionary constraint. This
result confirms how we need to consider
the ‘‘nonlinearity’’ of the HIV genome and
how amino acids that are some distance
apart in protein sequencemayhave critical
interactions within a three-dimensional
structure. An intriguing result in this paper
is that the HLA class I alleles enriched
among ‘‘elite HIV controllers’’—i.e., those
individuals who maintain low or undetect-
able viral loads without therapy—target
epitopes that contain more sites from
sector 3 than the other four sectors. This
result is surprising because the selectionImmunof sites within the sectors has been
cleaned or corrected for those that vary
becauseofHLAclass I-imposed selection,
andso thisfinding reflectsa separatepres-
sure driving coevolution. The argument is
that controllers target immune responses
against highly structurally conserved epi-
topes, and therefore escape mutations—
particularly multiple mutations—extract a
cost from HIV-1 so rendering it either
nonviable or of very low replication ca-
pacity. Although this is not a newargument
(these authors and others have previously
reported associations of viral fitness and
immune escape), this paper is unique
because it uses predictive mathematics
derived from physics and financial
forecasting.
Could these approaches contribute to
the design of an effective HIV vaccine?
The authors selected known epitopes
within the HIV proteome from an experi-
mental data set, which, although limited,
is representative for common HLA class
I alleles. By choosing a selection of
epitopes that contain the most sites from
sector 3 and which cover the most
common HLA class I alleles, the authors
propose that an immunogen could be de-
signed that could invoke T cell responses
in the majority of the population and for
which immune escape would be limited
by structural constraint and fitness costs.
Although other approaches have tackled
this question—and many papers on
HIV-1 fitness conclude by advocating
the consideration of fitness in vaccine
design—in this paper, a multidimensional
approach has been applied.
How can this approach be taken for-
ward? It is well known that virus se-
quenced from HIV controllers frequently
contains immune escapemutationswithin
key protective epitopes—often at sites
associated with fitness costs—and yet
virological control is maintained (Miura
et al., 2009). It is unlikely to be coincidence
thatmanyof theseescapemutationsoften
lie adjacent tomanyof the sites in sector 3,
although they are cleaned out by the RMT
method, which removes HLA-associated
sites. It might be interesting therefore to
consider sites not as independent amino
acids but rather as moving ‘‘epitope
windows’’ of 8–10 amino acids and see
whether the same sector structures are
realized. They may not be—complete
escape from an immune response can
result from a mutation at a single aminoity 35, July 22, 2011 ª2011 Elsevier Inc. 11
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Previewsacid within a 10 amino acid epitope, with
the other nine being highly conserved. An
effectiveHIV vaccine—whether protective
or therapeutic—is likely to be required to
confer both humoral and cell-mediated
protection. With the sorts of polydimen-
sional mathematical approaches de-
scribed by Dahirel et al. (2011), one might
envisage how the costs of all viral adapta-
tion could be considered together—
including adaptation to CTLs, broadly
neutralizing antibodies, and even antire-
troviral drugs—to predict a truly universal
immunogen. RMT is closely associated
with John von Neumann (von Neumann
and Goldstine, 1947), who was also in-
volved in the Manhattan Project working
out of Los Alamos and the first atomic
bomb. The decision to apply this concept
to HIV sequence data also from Los Ala-
mos is reminiscent of beating swords
into ploughshares. What would von Neu-12 Immunity 35, July 22, 2011 ª2011 Elseviemann make of this application of his
theory? Effective HIV vaccines remain
elusive but we are sure von Neumann
would approve of thismeritorious applica-
tion of his theory to data archived at Los
Alamos for the betterment, not the
destruction, of mankind.REFERENCES
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